| Document Date: 2013-09-21 15:10:26
Open Document File Size: 516,79 KBShare Result on Facebook
City Hamburg / Cambridge / / Company Astex Pharmaceuticals Inc. / / Event FDA Phase / / IndustryTerm 2HP-β-cyclodextrin solution / / MedicalCondition BRAF mutant melanoma / SK-MEL-28R tumours / relapsed tumours / Male SCID / melanoma / resistant melanoma / AKT -resistant preclinical melanoma / resistant tumours / BRAFV600E-driven melanoma / SCID / BRAFV600E melanoma / delay disease / xenograft tumours / tumour / Western blot. resistant tumours / tumours / / Person Keisha Hearn / Jon Lewis / Mohammad Azab / Neil Thompson / Nicola Wallis / Tomoko Smyth / John Lyons / / Product AT13387 / / URL www.astx.com / /
SocialTag |
Combining the HSP90 inhibitor, AT13387, with vemurafenib delays the emergence of V600E resistance in a preclinical model of BRAF mutant melanoma. Tomoko Smyth, Jon Lewis, Keisha Hearn, Neil Thompson, John Lyons, Mohammad